In Ohio, the Cleveland Clinic joined the Circulating Cell-free Genome Atlas, a national clinical trial that is looking for 7,000 cancer patients and 3,000 healthy patients in the U.S. Their goal is to analyze DNA and RNA in the blood and build a database that will help with detecting cancer early on when it is easier to cure. Researchers believe that using genome sequencing from blood samples could possibly replace x-rays for early cancer detection. Funded by a company in California, GRAIL, Inc., the project will be looking for molecule patterns in the blood for specific types of cancers.
Latest article
“Egg-cellent” idea: Onego Bio submits GRAS notification for chicken-free albumen
In the US, Finnish food ingredient company Onego Bio has officially submitted its Generally Recognized as Safe notification to the U.S. Food and Drug...
Researchers eye squid bone to rid the world of microplastics
In China, researchers from the University of Wuhan and Guangxi University have produced a fibrous, microplastics-attracting foam by combining cellulose fibers from cotton and...
Vollebak, Spiber team up for bioengineered garments
In London, clothing brand Vollebak has partnered with Japan’s Spiber, a company using molecular engineering to create biomaterial similar to spider silk, to create...